Core Insights - EUROAPI has signed a share purchase agreement for the sale of 100% of EUROAPI UK Ltd, which operates the Haverhill manufacturing site, to Particle Dynamics [1][2] - The divestment is part of EUROAPI's strategy to optimize its industrial footprint and advance its FOCUS-27 transformation plan, enhancing efficiency and focus on its strategic network [2] - The Haverhill site generated approximately 35 million euros in net sales in 2024, with nearly 80% attributed to Sanofi [2] Company Overview - EUROAPI is a leading player in active pharmaceutical ingredients, offering around 200 products and developing innovative molecules through its Contract Development and Manufacturing Organization (CDMO) activities [3] - The company operates six manufacturing sites in Europe and supplies customers in over 80 countries, emphasizing high-quality API manufacturing [4] - EUROAPI is listed on Euronext Paris under the ticker EAPI [4]

Core Viewpoint - EUROAPI has appointed Frédéric Robert as Chief Commercial Officer to enhance its API Solutions and CDMO activities, aligning with its FOCUS-27 transformation plan [1][3]. Group 1: Appointment and Responsibilities - Frédéric Robert will oversee the creation of commercial synergies between API Solutions and CDMO operations, aiming to deliver the FOCUS-27 sales plan and redefine the global sales strategy [2][3]. - His role includes expanding the group's presence in strategic markets and optimizing customer approaches with integrated, high-value-added solutions [2]. Group 2: Frédéric Robert's Background - Frédéric Robert has over 25 years of experience in the pharmaceutical industry, previously serving as Vice President of Sales & Customs Development EMEA at Aptar [4]. - He has held senior leadership roles at NAOS Bioderma and Fareva, where he led global commercial operations and was part of the Executive Committee [4]. Group 3: Company Overview - EUROAPI is a leading player in active pharmaceutical ingredients, with approximately 200 products in its portfolio and strong R&D capabilities [5][6]. - The company operates six manufacturing sites in Europe and supplies customers in over 80 countries [6].

Core Insights - EUROAPI has appointed Frédéric Robert as Chief Commercial Officer to enhance its API Solutions and CDMO activities, aligning with the FOCUS-27 transformation plan [1][3] - The new role will focus on creating synergies between API and CDMO operations, delivering the FOCUS-27 sales plan, and redefining the global sales strategy [2][3] Company Overview - EUROAPI is a leading producer of active pharmaceutical ingredients (API) and operates as a contract development and manufacturing organization (CDMO) [1][5] - The company offers approximately 200 products and has strong R&D capabilities with six manufacturing sites in Europe, serving customers in over 80 countries [5][6] Leadership Background - Frédéric Robert brings over 25 years of experience in the pharmaceutical industry, having held senior roles at companies like Aptar, Fareva, and NAOS Bioderma [3][4] - His expertise includes overseeing commercial operations across Europe and North America, providing a comprehensive understanding of the API and CDMO value chain [3][4]